SciSparc (SPRC) News Today $0.60 -0.12 (-16.81%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period SciSparc Ltd: SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementJanuary 16, 2025 | finanznachrichten.deSciSparc Granted Nasdaq Compliance ExtensionJanuary 15, 2025 | tipranks.comSciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementJanuary 15, 2025 | globenewswire.comSciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric VehiclesJanuary 13, 2025 | globenewswire.comSciSparc says MitoCareX expands research to pancreatic cancerJanuary 7, 2025 | markets.businessinsider.comSciSparc Ltd: SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive ResultsJanuary 7, 2025 | finanznachrichten.deSciSparc announces publication of European patent applicationJanuary 7, 2025 | markets.businessinsider.comSciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior TreatmentJanuary 7, 2025 | tipranks.comSciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive ResultsJanuary 7, 2025 | globenewswire.comSciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentJanuary 6, 2025 | globenewswire.comSciSparc announces renewal of approval by Israeli Medical Cannabis AgencyJanuary 1, 2025 | markets.businessinsider.comSciSparc Ltd. Renewed Approval for Clinical Trial of SCI-210 in Children with Autism Spectrum DisorderDecember 31, 2024 | quiverquant.comSciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum DisorderDecember 31, 2024 | globenewswire.comSciSparc Supports AutoMax’s $13 Million JAC Motors Vehicle ImportDecember 26, 2024 | tipranks.comSciSparc Shares Skyrocket With AutoMax's First JAC Motors ShipmentDecember 26, 2024 | benzinga.comSciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct ImportationDecember 26, 2024 | globenewswire.comSciSparc Ltd. Announces Amendment to LOI for Spin-Off of Pharmaceutical Assets Valued at Approximately $11.6 MillionDecember 16, 2024 | quiverquant.comSciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded CompanyDecember 16, 2024 | globenewswire.comSciSparc Ltd. to Acquire AutoMax Motors Ltd.November 29, 2024 | tipranks.comSciSparc Extends Merger Deadline with AutoMax MotorsNovember 27, 2024 | markets.businessinsider.comSciSparc Ltd. Reports Changes in Financial PositionNovember 5, 2024 | markets.businessinsider.comSciSparc Ltd. Reschedules Annual General MeetingOctober 23, 2024 | markets.businessinsider.comSciSparc Ltd. Gains Shareholder Approval for ProposalsOctober 23, 2024 | markets.businessinsider.comAthersys Inc (OTC:ATHX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSciSparc Ltd: SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentSeptember 30, 2024 | finanznachrichten.dePharma Company Gets FDA Green Light For Next Phase Trial For Tourette SyndromeSeptember 30, 2024 | benzinga.comSciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentSeptember 30, 2024 | globenewswire.comSciSparc Inks Non-binding LOI To Sell Its Entire Ownership Interest In MitoCareX BioSeptember 27, 2024 | markets.businessinsider.comSciSparc signs LOI to sell entire ownership in MitoCareXSeptember 26, 2024 | msn.comSciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareXSeptember 26, 2024 | globenewswire.comSciSparc Ltd: SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 24, 2024 | finanznachrichten.deSciSparc Says FDA OKs Initiation Of Phase IIb Clinical Trial For SCI-110 To Treat Tourette SyndromeSeptember 24, 2024 | markets.businessinsider.comSciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 23, 2024 | globenewswire.comSciSparc Ltd: SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 19, 2024 | finanznachrichten.deSciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentSeptember 18, 2024 | globenewswire.comSciSparc Ltd. (SPRC)September 18, 2024 | finance.yahoo.comSciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination TherapySeptember 16, 2024 | globenewswire.comSciSparc Slides Following AutoMax DealSeptember 11, 2024 | msn.comSciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle ManufacturerSeptember 11, 2024 | globenewswire.comSciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentSeptember 6, 2024 | globenewswire.comSciSparc (NASDAQ:SPRC) Stock Quotes, Forecast and News SummaryAugust 30, 2024 | benzinga.comSciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based CombinationAugust 29, 2024 | globenewswire.comSciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 MillionAugust 28, 2024 | globenewswire.comSciSparc Ltd: SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette SyndromeAugust 24, 2024 | finanznachrichten.deSciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette SyndromeAugust 23, 2024 | globenewswire.comSciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory BoardAugust 22, 2024 | globenewswire.comSciSparc and Polyrizon sign global agreement for pain therapyAugust 20, 2024 | msn.comSciSparc Ltd: SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 TreatmentAugust 20, 2024 | finanznachrichten.deIsraeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain TherapyAugust 19, 2024 | msn.comSciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 TreatmentAugust 19, 2024 | globenewswire.com Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRC Media Mentions By Week SPRC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRC News Sentiment▼0.610.49▲Average Medical News Sentiment SPRC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRC Articles This Week▼31▲SPRC Articles Average Week Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OCX News OKYO News OMGA News SLGL News PMN News RNXT News AKTX News IXHL News LSTA News CGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
